Histological section of a ciliary body. Credit: University of Bristol
A new study led by the University of Bristol has shown a common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients.
Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight. Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.
The research team led by academics at the Bristol Medical School: Translational Health Sciences tested a new approach that could provide additional treatment options and benefits. Their findings are published in the journal Molecular Therapy.
The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.
The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye. Using the latest gene editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.
Dr Colin Chu, Visiting Senior Research Fellow in the Bristol Medical School: Translational Health Sciences and corresponding author, said: “Currently there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early.
“We hope to advance towards clinical trials for this new treatment in the near future. If it’s successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money.”
The academics are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Glaucoma
- How to spot serious condition that can make you blind as 84% of Brits oblivious to signs
Research found that most people in the UK are unaware of the early signs of glaucoma, which include headaches, nausea, seeing multi-coloured halos and the loss of peripheral vision ...
- Too many glaucoma cases go undetected. Startup Eyeonic wants to change that
Associate Professor Simon Skalicky is the man behind Eyeonic, a medtech startup that promises to make glaucoma testing easier and more accessible the world over. An opthalmologist by trade, he ...
- Inclusivity and accessibility top of mind for Edmonton fitness trainer
Erika Sikat has made her company all about accessibility and inclusion, where anyone can enter a gym and feel welcome and heard.
- Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%
The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market size is expected to reach USD 10.5 Billion by 2032, according to a research ...
- Mass Eye and Ear researchers create possible glaucoma treatment strategy to direct stem cells to retina
In the study, researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and ...
Go deeper with Google Headlines on:
Glaucoma
[google_news title=”” keyword=”glaucoma” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Glaucoma gene therapy
- Potential glaucoma treatment strategy to guide stem cells to the retina
Scientists have developed a novel approach that allows stem cells to be turned into retinal ganglion cells that are capable of migrating and surviving in the eye's retina. This approach presents a ...
- Researchers identify a promising new strategy for glaucoma cell replacement therapy
Now, a multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.
- From Data To Diagnosis: A Deep Learning Approach To Glaucoma Detection
I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal. Glaucoma is a leading cause of irreversible ...
- New medical treatments will use genetic scissors, and other clever tricks
Crispr Therapeutics is developing similar technology to create replacement insulin-producing cells in the pancreas. There are also efforts to develop “in vivo” gene editing, to allow gene-editing ...
- Glaucoma is Undertreated Among Minorities | AAO 2023
Racial disparities in glaucoma care persist, regardless of socioeconomic status, finds new research presented at the annual meeting of the American Academy of Ophthalmology. Patients with glaucoma who ...
Go deeper with Google Headlines on:
Glaucoma gene therapy
[google_news title=”” keyword=”glaucoma gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]